NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more
NewAmsterdam Pharma Company N.V. Warrant (NAMSW) - Net Assets
Latest net assets as of September 2025: $728.07 Million USD
Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Warrant (NAMSW) has net assets worth $728.07 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($786.43 Million) and total liabilities ($58.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $728.07 Million |
| % of Total Assets | 92.58% |
| Annual Growth Rate | 56.14% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 287.66 |
NewAmsterdam Pharma Company N.V. Warrant - Net Assets Trend (2020–2024)
This chart illustrates how NewAmsterdam Pharma Company N.V. Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NewAmsterdam Pharma Company N.V. Warrant (2020–2024)
The table below shows the annual net assets of NewAmsterdam Pharma Company N.V. Warrant from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $757.50 Million | +162.66% |
| 2023-12-31 | $288.39 Million | -32.94% |
| 2022-12-31 | $430.07 Million | +659.49% |
| 2021-12-31 | $56.63 Million | -55.57% |
| 2020-12-31 | $127.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NewAmsterdam Pharma Company N.V. Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1347580.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.44 Million | 1.77% |
| Other Comprehensive Income | $4.47 Million | 0.59% |
| Other Components | $1.30 Billion | 171.37% |
| Total Equity | $757.50 Million | 100.00% |
NewAmsterdam Pharma Company N.V. Warrant Competitors by Market Cap
The table below lists competitors of NewAmsterdam Pharma Company N.V. Warrant ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Richelieu Hardware Ltd
PINK:RHUHF
|
$1.16 Billion |
|
Invisio AB
LSE:0R86
|
$1.16 Billion |
|
Mr D.I.Y. Group (M) Berhad
OTCGREY:MDIYF
|
$1.16 Billion |
|
Nickel Industries Ltd
AU:NIC
|
$1.16 Billion |
|
ACC Limited
NSE:ACC
|
$1.16 Billion |
|
Beijing Cisri Gaona Materials Tech
SHE:300034
|
$1.15 Billion |
|
Shenzhen Aisidi Co Ltd
SHE:002416
|
$1.15 Billion |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
$1.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NewAmsterdam Pharma Company N.V. Warrant's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 288,393,000 to 757,500,000, a change of 469,107,000 (162.7%).
- Net loss of 241,598,000 reduced equity.
- New share issuances of 645,507,000 increased equity.
- Other comprehensive income increased equity by 45,000.
- Other factors increased equity by 65,153,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-241.60 Million | -31.89% |
| Share Issuances | $645.51 Million | +85.22% |
| Other Comprehensive Income | $45.00K | +0.01% |
| Other Changes | $65.15 Million | +8.6% |
| Total Change | $- | 162.66% |
Book Value vs Market Value Analysis
This analysis compares NewAmsterdam Pharma Company N.V. Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.58x to 2.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $7.18 | $18.50 | x |
| 2021-12-31 | $3.19 | $18.50 | x |
| 2022-12-31 | $22.68 | $18.50 | x |
| 2023-12-31 | $3.51 | $18.50 | x |
| 2024-12-31 | $8.03 | $18.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NewAmsterdam Pharma Company N.V. Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -530.25%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.14x
- Recent ROE (-31.89%) is above the historical average (-35.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -5.51% | 0.00% | 0.00x | 1.10x | $-19.77 Million |
| 2021 | -73.79% | 0.00% | 0.00x | 1.20x | $-47.45 Million |
| 2022 | -5.26% | -22.04% | 0.21x | 1.11x | $-65.64 Million |
| 2023 | -61.35% | -1255.76% | 0.04x | 1.20x | $-205.78 Million |
| 2024 | -31.89% | -530.25% | 0.05x | 1.14x | $-317.35 Million |
Industry Comparison
This section compares NewAmsterdam Pharma Company N.V. Warrant's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. Warrant (NAMSW) | $728.07 Million | -5.51% | 0.08x | $1.16 Billion |
| Abcam plc (ABCZF) | $15.07 Million | 22.73% | 0.21x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $7.09 Million | -104.63% | 5.72x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.71 Million |
| Adamas Trust, Inc. (ADAMG) | $1.41 Billion | -4.40% | 5.53x | $2.07 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $13.74 Million | 0.00% | 2.67x | $9.38 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $51.99 Million | -0.21% | 3.57x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $1.03 Million | -345.23% | 6.23x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $2.41 Billion | -5.83% | 0.11x | $119.23K |
| Alvotech Warrant (ALVOW) | $-412.77 Million | 0.00% | 0.00x | $35.01 Million |